The Effect of CYP3A Genetic Polymorphism on the Pharmacokinetics of Phosphodiesterase type5 Inhibitors in Male Subjects

NCT00767598 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Pharmacokinetics of Three PDE5Is
Healthy Subjects
Genetic Polymorphic CYP3A5

Interventions

DRUG: phosphodiesterase type 5 inhibitor
DRUG: phosphodiesterase type 5 inhibitor
DRUG: phosphodiesterase type 5 inhibitor

Sponsor

Inje University